Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 9/20 | 0.43 |
| ▸ | PIK3R2 | O00459 | 3/20 | 0.43 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.40 |
| ▸ | KRAS | P01116 | 2/20 | 0.38 |
| ▸ | MC4R | P32245 | 2/20 | 0.35 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.34 |
| ▸ | IGF1R | P08069 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14481299 | 0.92 | PIK3CD (0.45) | PIK3CDPIK3R2PIK3CGKRASMC4R | |
| SCHEMBL14481060 | 0.89 | PIK3CD (0.46) | PIK3CDPIK3R2PIK3CGKRASP2RX3 | |
| SCHEMBL14481052 | 0.88 | PIK3CD (0.40) | PIK3CDKRASIGF1R | |
| SCHEMBL15899853 | 0.87 | PIK3CD (0.39) | PIK3CDPIK3R2P2RX3 | |
| SCHEMBL14480865 | 0.85 | PIK3CD (0.45) | PIK3CDPIK3R2PIK3CGKRAS | |
| SCHEMBL14480870 | 0.85 | PIK3CD (0.45) | PIK3CDPIK3R2PIK3CGKRAS | |
| SCHEMBL14480944 | 0.85 | PIK3CD (0.44) | PIK3CDPIK3R2PIK3CGKRAS | |
| Formic Acid SCHEMBL14481352 | 0.84 | PIK3CD (0.38) | PIK3CDPIK3R2KRASP2RX3 | |
| SCHEMBL14481241 | 0.84 | PIK3CD (0.44) | PIK3CDPIK3R2PIK3CGKRAS | |
| SCHEMBL14574626 | 0.84 | PIK3CD (0.39) | PIK3CDP2RX3IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2499129-B1 | QUINOLINE AND QUINOXALINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2014-07-30 | — | — | EP | claimed |
| US-8653105-B2 | Quinoline derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2014-02-18 | — | — | US | claimed |
| US-20130012517-A1 | Quinoline and Quinoxaline Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2013-01-10 | — | — | US | claimed |
| EP-2499129-B1 | QUINOLINE AND QUINOXALINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2014-07-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012517-A1 | Quinoline and Quinoxaline Derivatives as Kinase Inhibitors | PDXK, MAP2K2, PDPK1 | PIK3CD 13/4885PIK3R2 106/4885PIK3CG 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.